Patents Represented by Attorney William Peter Long
  • Patent number: 8236931
    Abstract: An inhibitor of the aggregation of immunoglobulin chains is provided. The inhibitor may comprise or consist of a polypeptide which comprises or consists of (a) an amino acid sequence corresponding to the amino acid sequence of the FR1 region of an immunoglobulin light chain variable domain, or part thereof which includes amino acid residue 12, (b) an amino acid sequence corresponding to the amino acid sequence of the immunoglobulin-binding domain of bacterial superantigen Protein L, or part thereof, and/or (c) an amino acid sequence corresponding to the amino acid sequence of the immunoglobulin-binding domain of streptococcal protein G, or part thereof, or a variant, fusion or derivative thereof, or a fusion of a variant or derivative thereof which retains the ability of the parent polypeptide to inhibit aggregation of immunoglobulin chains, or domains thereof. Other versions of the inhibitor are also provided.
    Type: Grant
    Filed: October 26, 2007
    Date of Patent: August 7, 2012
    Assignee: Glaxo Group Limited
    Inventors: Rudolf M. T. De Wildt, Leo C James, Philip C Jones, Oliver Schon, Gregory Paul Winter
  • Patent number: 8133978
    Abstract: The present invention discloses humanised anti-IL-18 antibodies, methods of manufacture, and methods of treatment with said antibodies. Further disclosed are screening methods using for example surface plasmon resonance to identify antibodies with therapeutic potential.
    Type: Grant
    Filed: May 23, 2007
    Date of Patent: March 13, 2012
    Assignee: Glaxo Group Limited
    Inventors: Jonathan Henry Ellis, Volker Germaschewski, Paul Andrew Hamblin
  • Patent number: 8129503
    Abstract: Disclosed is the use of an agent (e.g., antibody fragment, antagonist, ligand, dAb monomer) that binds a target in pulmonary tissue for the manufacture of a long action or long therapeutic window formulation for local delivery to pulmonary tissue, and methods for administering an agent that binds a target in pulmonary tissue to a subject to produce a long therapeutic window in pulmonary tissue. The formulation is for, and the method comprises, administering locally to pulmonary tissue. Also disclosed is the use of antagonists of TNFR1 for the manufacture of a formulation or medicament for treating, preventing or suppressing lung inflammation or a respiratory disease, and methods of treating such diseases. Also disclosed are the use of agents a for the manufacture of a delivery device (e.g.
    Type: Grant
    Filed: October 23, 2006
    Date of Patent: March 6, 2012
    Assignee: Domantis Limited
    Inventors: Rudolf M. T. de Wildt, Steve Holmes, Ian M. Tomlinson, Gregory P. Winter, Mary F. Fitzgerald, Justian Craig Fox, Armin Sepp, Jennifer Luckett, Benjamin P. Woolven
  • Patent number: 8084213
    Abstract: The present invention to a nucleotide sequence encoding one or more Arc DNA binding domains, one or more Arc DNA binding sites and at least one polypeptide domain.
    Type: Grant
    Filed: January 17, 2007
    Date of Patent: December 27, 2011
    Assignee: Domantis Limited
    Inventors: Armin Sepp, Andrew Griffiths
  • Patent number: 7982005
    Abstract: Chimeric, humanized and other IL-5 mAbs, derived from high affinity neutralizing mAbs, pharmaceutical compositions containing same, methods of treatment and diagnostics are provided.
    Type: Grant
    Filed: March 1, 2010
    Date of Patent: July 19, 2011
    Assignee: GlaxoSmithKline LLC
    Inventors: Robert S. Ames, Edward Robert Appelbaum, Irwin M. Chaiken, Richard M. Cook, Mitchell Stuart Gross, Stephen Dudley Holmes, Lynette Jane McMillan, Timothy Wayne Theisen
  • Patent number: 7939074
    Abstract: A combination of an anti-Ep-CAM antibody with a chemotherapeutic agent that is capable of arresting Ep-CAM antigen expressing cells in S or G2/M.
    Type: Grant
    Filed: January 8, 2010
    Date of Patent: May 10, 2011
    Assignee: GlaxoSmithKline LLC
    Inventors: Vincent C. Knick, Julie Beth Stimmel, Linda M. Thurmond
  • Patent number: 7846721
    Abstract: Disclosed is a polynucleotide molecule comprising a promoter operably linked to a nucleic acid sequence encoding a GAS1 secretion signal peptide, wherein said promoter is not a rhamnose promoter.
    Type: Grant
    Filed: July 27, 2006
    Date of Patent: December 7, 2010
    Assignee: Domantis Limited
    Inventor: Rudolph M. T. DeWildt